Biomarkers for radiation treatment
US10844437B2 · kind B2 · utility
0Cited by
1References
17Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 6, 2018 |
| Grant date | Nov 24, 2020 |
| Priority date | — |
| Expiry date | Oct 18, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2400/40
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The methods described herein allow for the classification of patients into groups for receiving optimized radiation treatment based on patient specific biomarker signature. The biomarker signature includes markers that have been shown to correlate with TGF-B expression and to be associated with tumor aggressiveness, radioresistance and poor prognosis. The markers play a key role in the epithelial-mesenchymal transition. The methods described herein provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining TGF-B inhibitors with ionizing radiation to treat cancer patients.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.